Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Adam Kittai, MD, of the Icahn School of Medicine, describes three trials on novel therapies for Richter transformation.
The findings from a real-world setting were consistent with previous studies and no new safety signals were found.
Liso-cel monotherapy was found to be effective even in patients with high-risk disease features.
The study's results illustrate the effects of these abnormalities and the importance of screening.
Over a three-year study period ibrutinib use in the US decreased while acalabrutinib and zanubrutinib use increased.
A study identified CLL disease mechanisms that are based in the ncBAF complex interactome.
Advertisement
Spearman's Rho calculations at the patient level indicated a strong correlation between PFS and OS.
A biospecimen study found an approximately doubled risk for melanoma in low-count MBL.
The newer agents have distinguished themselves especially by having safety profiles superior to ibrutinib.
Dr. Rogers debated against Inhye Ahn, MD, on whether therapy with Bruton tyrosine kinase inhibitors can be discontinued.
Dr. Coombs discussed time limited therapies and the phase III AMPLIFY trial of acalabrutinib plus venetoclax in CLL.
Liso-cel demonstrated clinical benefit and manageable safety, with low incidences of grade ≥3 CRS.
Fixed-duration ibrutinib plus venetoclax provides durable PFS in patients with CLL.
Ibrutinib provides significantly longer PFS and OS benefits in CLL when compared to chlorambucil.
Oral targeted inhibitors are a viable treatment for patients with CLL with severe renal dysfunction.
Switching rates within 60 days were lower for patients treated with zanubrutinib compared with acalabrutinib and ibrutinib.
The past year in CLL care has seen promising new study findings on BTK inhibition and regulatory approvals.
A first ever phase I/II trial tested escalating doses in patients with relapsed or refractory disease.
A genetic axis pertaining to cell oxidative phosphorylation in RT may be an actionable therapy target to extend survival.
In a phase III study the regimen compared favorably with chlorambucil plus obinutuzumab in its survival outcomes.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.